Clinical Trials
3 trialsNCT03837899 2026-04-21
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
Phase 1/2 Active not recruiting
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT03206073 2023-10-24
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed